Launches fuel Novartis’ growth as CEO reiterates China commitment

With over 90% commercial payer coverage for SMA gene therapy Zolgensma and increased uptake for heart failure drug Entresto, Novartis posted nearly double-digit sales growth in 2019 as the pharma looks to additional new drugs to sustain its momentum.

CEO Vasant Narasimhan also reiterated the pharma’s commitment to growth of its innovative medicines business in China as the Swiss pharma delivered its 4Q19 and 2019 earnings...